J Korean Geriatr Soc.
2007 Jun;11(2):74-82.
Effect of Galantamine on Caregiver Time and Activities of Daily Living in Mild to Moderate Alzheimer's Disease: A 1-Year Prospective Study
- Affiliations
-
- 1Department of Psychiatry, Hallym University College of Medicine, Seoul, Korea. suhgh@chol.com
- 2Department of Psychiatry, Seoul National University, Boramae Hospital, Seoul, Korea.
- 3Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.
- 4Jeonju Elderly Hospital, Iksan, Korea.
- 5Department of Psychiatry, Won Kwang University College of Medicine, Iksan, Korea.
- 6Department of Psychiatry, Chung-Ang University College of Medicine, Seoul, Korea.
- 7Department of Psychiatry, Inje University College of Medicine, Seoul, Korea.
- 8Janssen Korea Pharmaceutical, Seoul, Korea.
- 9Global Clinical R&D, Johnson and Johnson Pharmaceutical Research and Development, New Jersey, New York, United States.
Abstract
OBJECTIVE
This study aims to investigate the effect of galantamine on caregiver time and activities of daily living(ADLs) in patients with mild to moderate Alzheimer's disease(AD) in a Korean population. DESIGN: Quasi-experimental study: A rndomized, double-blind, parallel-group clinical trial and a naturalistic longitudinal community study METHOD: For this 1-year prospective study, 138 patients residing in the community were recruited(baseline MMSE score of. 10-22). The two groups were composed of 72 patients treated with galantamine and 66 patients selected as the control group from an untreated community cohort of AD patients. The primary efficacy outcome was the caregiver time and the secondary efficacy measure was the Korean version of the Disability Assessment for Dementia(DAD-K) scale.
RESULTS
The results of a mixed model analyses demonstrated reduced caregiver time and improved ADLs in galantamine group relative to baseline and compared with the community control group in this 1-year prospective study. Significant improvement in galantamine group observed in the DAD scores demonstrated beneficial effects of galantamine on delaying functional deterioration in patients with mild to moderate AD. Difference in caregiver time between two groups was equivalent to additional 9.5 working days per month or 113 working days per year.
CONCLUSION
Treatment with Galantamine is associated with a significantly slower decline in basic and instrumental ADLs in patients with mild to moderated AD. These benefits on functional capacity in patients with AD treated with galantamine were associated with less caregiver time, lower caregiver burden and higher economic benefits.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Economic and Clinical Benefits of Galantamine in the Treatment of Mild to Moderate Alzheimer's Disease in a Korean Population: A 52-Week Prospective Study
- The Effects of Galantamine Treatment on Attention and Its Relationship with Cognition and Activities of Daily Living in Patients with Mild to Moderate Alzheimer's Disease
- Effects of Galantamine Treatment on Attention, Activities of Daily Living, and Neuropsychiatric Symptoms between the Patients with Pure Alzheimer's Disease and Mixed Dementia
- Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
- Effect of Physical Disability on Instrumental Activities of Daily Living in Alzheimer's Disease, Amnestic Mild Cognitive Impairment (MCI), and Vascular Dementia and Vascular MCI of Subcortical Type
